Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Imran Zainal Abidin, Ciaran J. McMullan et al.|The Lancet|2025Cited by 77
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaı̈ez Zannad, Nicholas Ryan, Christopher M. O’Connor et al.|The Lancet|2025Cited by 39
Baseline Characteristic Of Participants In The Victor (Vericiguat Global Study In Participants With Chronic Heart Failure) Trial Global Study In Participants With Chronic Heart Failure) Trial:Faiez Zannad, Javed Butler, Stefano Corda et al.|Journal of Cardiac Failure|2025Cited by 0